ArticleInfectious diseases and therapy2025
Efficacy of Topical Antifungal Nail Solution Versus Topical Placebo Solution for the Treatment of Pedal Onychomycosis: A Randomized Controlled Trial.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionPedal onychomycosis is common, and its treatment entails debridement combined with topical and/or oral antifungal medication.
methodsIn this study, 69 participants were randomly allocated to either active (31 [44.93%]) or placebo (38 [55.07%]) topical solution. The primary outcome was mycological cure, and secondary outcomes included visible nail plate involvement and toenail-related quality of life.
resultsAfter a minimum duration of follow-up of 7 months and a maximum of 9 months, participants in the active solution group experienced statistically significantly greater mycological cure (1 [2.63%] placebo versus 17 [54.84%] active, p < 0.0001) and clinical cure (2 [5.56%] placebo versus 21 [70%] active, p < 0.0001), including 47.62% of which showed complete clearance of visible nail plate involvement with no residual gross nail plate dystrophy and improved toenail-related quality of life, including less symptom bothersomeness (p < 0.0344), less overall toenail problems (p < 0.0315), and greater satisfaction with treatment (p < 0.0195) as early as the 3-month follow-up visit. In addition, the active solution group experienced less frequent symptoms (p = 0.0046 at 9 months) and symptom bothersomeness (p = 0.0002 at 7 months, < 0.0001 at 9 months), less difficulty caring for toenails and better toenail appearance (p = 0.0250 at 7 months, p= 0.007 at 9 months), improved physical activity and less toenail pain (p = 0.0208 at 7 months, p = 0.003 at 9 months), less overall toenail problems (p = 0.0002 at 7 months, p = 0.0006 at 9 months), and greater treatment satisfaction (p = 0.0003 at 7 months, p = 0.0015 at 9 months).
conclusionsParticipants with pedal onychomycosis that were randomized to the active topical solution showed statistically significantly greater mycological and clinical cures, as well as improved quality of life, in comparison with those allocated to the placebo topical solution.
trial registrationISRCTN Protocol no. 77852934.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.